Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Novelos Out-Licenses China Rights for Two Compounds

publication date: Dec 18, 2007

Novelos Therapeutics has out-licensed the China rights for two compounds, which are aimed at treating cancer and hepatitis patients, to Lee’s Pharmaceutical Ltd. (HK: 8221) of Hong Kong. Lee’s Pharma will be responsible for all clinical development, regulatory filings and commercialization of the compounds in China. Both compounds were originally developed in Russia, and they are approved for use there, where they have been administered to over 10,000 patients. Novelos owned all ex-Russia rights for the compounds. More details...

Stock Symbols: (OTCBB: NVLT) (HK: 8221)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital